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Background. Conventional cardiac risk scores may not be completely accurate in predicting acute events
because they only include factors associated with atherosclerosis, considered as the fundamental precursor of
cardiovascular disease. In UK in 2006–2008 (Whitehall II study) we tested the ability of several risk scores to
identify individuals with cardiac cell damage and assessed to what extent their estimates were mediated by
the presence of atherosclerosis.
Methods. 430 disease-free, low-risk participants were tested for high-sensitivity cardiac troponin-T (HS-
CTnT) and for coronary calciﬁcation using electron-beam, dual-source, computed tomography (CAC). We
analysed the data cross-sectionally using ROC curves and mediation tests.
Results.When the risk scoreswere ranked according to themagnitude of ROC areas for HS-CTnT prediction, a
score based only on age and gender came ﬁrst (ROC area = 0.79), followed by Q-Risk2 (0.76), Framingham
(0.70), Joint-British-Societies (0.69) and Assign (0.68). However, when the scores were ranked according to
the extent of mediation by CAC (proportion of association mediated), their order was essentially reversed
(age&gender = 6.8%, Q-Risk2 = 9.7%, Framingham = 16.9%, JBS = 17.8%, Assign = 17.7%). Therefore, the
more accurate a score is in predicting detectable HS-CTnT, the less it is mediated by CAC; i.e. the more able a
score is in capturing atherosclerosis the less it is able to predict cardiac damage. The P for trend was 0.009.
Conclusions. The dynamics throughwhich cardiac cell damage is caused cannot be explained by ‘classic’ heart
disease risk factors alone. Further research is needed to identify precursors of heart disease other than
atherosclerosis.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Background
The pathophysiology of heart disease has been studied for centuries
(Nabel & Braunwald, 2012) and our knowledge of the disease has under-
gone a remarkable evolution during the past decade (Libby, 2013). Coro-
nary atherosclerosis, indicated as the fundamental precursor of coronary
artery disease, was previously considered as a passive cholesterol storage
disease whereas we currently view it as an inﬂammatory disorder and
modern views of the dynamics underlying acute cardiac events also high-
light the role of inﬂammation. Therefore our understanding of phenome-
na such as lesion formation, arterial remodelling, plaque rupture,
thrombosis, and others will likely continue to evolve (Libby, 2013).
Risk assessment is an important part of routine clinical practice, and
tools for the prediction of coronary artery disease (CAD) events in
healthy subjects and the correlated administration of preventive cures
have a long history (About the Framingham Heart Study). However, in
spite of our constant progress in the comprehension of CAD pathophys-
iology, standard risk algorithms are based on the idea that cardiac
events arise through the accumulation of coronary atherosclerosis and
widely-used tools like the Framingham, the Joint British Societies &
British National Formulary, the Assign, and the Q-Risk scores are still
based on variables such as age, gender, blood lipids, blood pressure,
and other ‘classic’ risk factors associated with atherosclerosis, as it was
traditionally conceived (D'Agostino et al., 2008; British Cardiac Society
et al., 2005; Woodward et al., 2007; Hippisley-Cox et al., 2008). The
standard risk algorithms may not therefore be completely accurate in
predicting cardiac events, rather than coronary stenosis, because they
only include factors associated with ‘passive’ atherosclerosis, consid-
ered as the main mediator for CAD events.
Cardiac Troponin T (CTnT) is a plasma protein routinely tested for
the diagnosis of acute myocardial infarction (AMI), since it is a marker
of myocardial cell damage (Thygesen et al., 2007). In clinical settings,
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CTnT is measured using standard assays that have a lower detection
limit of 10 ng/L (Wallace et al., 2006) and a diagnostic threshold of
35 ng/L (Thygesen et al., 2007; Wallace et al., 2006). However, high-
sensitivity assays have recently been developed (HS-CTnT) with a
lower detection limit of 3 ng/L (Giannitsis et al., 2010; Collinson,
2011; Collinson et al., 2012). In healthy people not fulﬁlling any
diagnostic criterion for AMI, greater HS-CTnT is associated with greater
incidence of AMI, other structural and functional heart diseases, cardio-
vascularmortality, and all-causemortality, and can be therefore consid-
ered the most proximal sentinel marker of heart disease (De Lemos
et al., 2010; deFilippi et al., 2010).
The mechanisms and clinical relevance of HS-CTnT in apparently
low risk participants remains poorly understood, and further research
is needed to understand if HS-CTnT should be included in screening
tools as part of routine clinical practice. However, identifying groups
of people with low risk proﬁle, absent coronary calciﬁcation, but with
detectableHS-CTnTwould create amomentum towards the exploration
of new pathophysiologic dynamics of heart disease.
The aim of this study was to test the ability of the Framingham, the
Joint British Societies & British National Formulary (JBS/BNF), the
Assign, and the Q-Risk 2 scores to identify individuals with detectable
HS-CTnT plasma concentration in people with and without apparent
atherosclerosis as deﬁned by coronary artery calciﬁcation (CAC) and
to assess to what extent their estimates are mediated by CAC.
Methods
Study design
Our cross-sectional study involved participants drawn from theWhitehall II
epidemiological cohort (Marmot et al., 1991) between 2006 and 2008 in United
Kingdom. The criteria for entry into the study included no history or objective
signs of clinical or subclinical CVD, no previous diagnosis or treatment for hy-
pertension, inﬂammatory diseases, allergies, or kidney disease. CVDwasdeﬁned
as prior myocardial infarction, stable or unstable angina, revascularization pro-
cedure, heart failure, transitory ischaemic attack, stroke, or electrocardiographic
abnormalities (resting 12-lead electrocardiograms were taken). This informa-
tion was conﬁrmed by a telephone interview and veriﬁed from clinical data
collected from the previous seven phases of the Whitehall II study. Volunteers
were of white European origin, aged 53–76 years, and 56.5% were in full-time
employment. Selection was stratiﬁed by grade of employment (current or
most recent) to include higher and lower socioeconomic status participants.
From the initially invited participants (n = 1169), 27.6% were not eligible
(mainly because of prescribed medications) and 25.9% declined to take part.
Participants were prohibited from using any medication from seven days
before testing and were rescheduled if they reported colds or other infections
on the day of testing. Participants gave full informed consent to participate in
the study and ethical approval was obtained from the UCLH committee on the
Ethics of Human Research. The study conformed to the principles of the decla-
ration of Helsinki.
Data collection
Non-fasting blood samples were collected in EDTA tubes and centrifuged
immediately at 2500 rpm for 10min at room temperature. Plasmawas removed
from the tube and aliquoted into 0.5 ml portions and stored at 80 °C until anal-
ysis. We measured cardiac troponin T concentrations using a highly sensitive
assay on an automated platform (Elecsys-2010 Troponin T hs STAT, Roche Diag-
nostics), with a lower detection limit of 3 ng/L and a reported 99th percentile
value in apparently healthy individuals of 13.5 ng/L, at which the CV is 9%, con-
ﬁrmed by in house studies (Giannitsis et al., 2010; Collinson, 2011; Collinson
et al., 2012).
The assessment of coronary artery calciﬁcation (CAC) was performed using
electron beam computed tomography (GE Imatron C-150, San Francisco, CA,
USA) as previously described (Anand et al., 2007). In brief, 40 contiguous
3 mm slices were obtained during a single breath-hold starting at the carina
and proceeding to the level of the diaphragm. Scan time was 100 ms/slice, syn-
chronized to 40% of the R-R interval. Agatston and volumetric calcium scores
were calculated to quantify the extent of CAC by a single experienced investiga-
tor blinded to the psychophysiological and clinical data on an Aquarius
workstation (TeraRecon Inc., San Mateo, CA, USA). Since calciﬁed volume was
very highly correlatedwith Agatston score (Spearman's rho=0.99),wepresent
data for Agatston score only.
Participants reported current smoking levels. We measured height and
weight in light clothing for the calculation of body mass index (BMI). Fasting
blood samples were taken during a separate clinical assessment. Total and
high-density lipoprotein (HDL) cholesterol and triglycerides were measured
within 72 h in serum stored at 4 °C using enzymatic colorimetric methods
(Brunner et al., 1997). Low-density lipoprotein (LDL) cholesterol was derived
using the Friedewald equation (Warnick et al., 1990). Glucose homeostasis
was assessed from glycated haemoglobin (HbA1C) concentration, assayed
using boronate afﬁnity chromatography, a combination of boronate afﬁnity
and liquid chromatography.
Data analysis
Data analysis was performed using Stata v.13. We checked the dataset
for missing and inconsistent values, as well as normality, outliers, and digit
preference for linear variables. We excluded 83/543 people (15.3%) with
prescribed statins or diabetes. Out of the remaining 460 participants, 30
(6.5%) had missing information for HS-CTnT due to insufﬁcient blood sam-
ples, and the ﬁnal analytic sample therefore comprised 430 people. HS-CTnT
was highly right-skewed and for 83.3% (n = 358) of the sample it was
undetectable (below the lower detection limit of 3 ng/L) and so it was trans-
formed into a binary variable (detectable vs undetectable). We calculated the
Framingham (general CVD, primary model), the JBS/BNF, the Assign, and the
Q-Risk2 scores for the risk of CVD events within ten years using information
about age, gender, total cholesterol, HDL, systolic blood pressure, smoking,
diabetes, history of CVD (not for Assign), family history of CVD (not for
Framingham and JBS/BNF), BMI (Q-Risk2 only), ethnicity (Q-Risk2 only), and
rheumatoid arthritis (Q-Risk2 only) (D'Agostino et al., 2008; British Cardiac
Society et al., 2005; Woodward et al., 2007; Hippisley-Cox et al., 2008). The
computation of the Assign and the Q-Risk2 algorithms includes optional vari-
ables consisting of area-based socio-economic deprivation scores for UK, and
we opted to use their default values (20 for Assign and zero for Q-Risk2) so
that the predictions were based on clinical variables only and were therefore
comparable to the ones from the other algorithms, which do not consider
such variables. We also calculated a simple risk score based on age and gender
only. To do this we ﬁtted a logistic regression model with age and gender as co-
variates and HS-CTnT as outcome and calculated the predicted probability of
HS-CTnT prevalence (Cleves, 2002).
We performed non-parametric ROC analysis to assess the accuracy of each
risk score in predicting the presence of detectable HS-CTnT and compared
each of these estimateswith the one based on age and gender alone (reference).
We used binary mediation analysis to assess to what extent the association
between each risk score and HS-CTnTwasmediated by CAC (Stata FAQ). In par-
ticular, we calculated the proportion of the effect that is mediated (Stata FAQ)
and its 95% conﬁdence intervals using bootstrapping (1000 replications)
(Mooney, 1993). Similarly to the ROC analysis, we used the score based on
age and gender as the referent equation for the comparisons.
We performed a statistical test for trend using the following strategy: we
constructed a 5 × 2 table containing the results from the ROC analysis and
from themediation analysis for each score and calculated a P for trend using lin-
ear regression.
Sensitivity analyses
We considered CAC in several different ways: linear; log-linear; binary with
a cut-off at zero; binarywith a cut-off at 100 (this thresholdwas based on the St
Francis Heart Study that demonstrated maximum sensitivity and speciﬁcity for
detecting cardiovascular events at a threshold calcium score ≥ 100 (Arad et al.,
2005)); and ordered categorical with cut-offs at 0, 100, and 400. The score
based on age and gender was calculated including an interaction term between
age and gender (multiplicative model) since risk algorithms are usually gender
speciﬁc. A second score based on age and gender was calculated including
measures of systemic inﬂammation (Interleukin-6 and C-reactive protein)
since they are considered as novel risk factors for CVD. Instead of ﬁtting the
ROC models using the risk scores directly, we used the same procedure as for
age and gender, i.e. we ﬁrst ﬁtted a logistic regression model using the risk
score as exposure and HT-CTnT as outcome, we then calculated the predicted
probabilities, and then used those to ﬁt the ROC model (Cleves, 2002). We
used linear (Stata FAQ) instead of binary mediation.
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Results
Out of the 430 participants in our ﬁnal dataset, none had been pre-
scribed anti-hypertensive treatment or statins or had diabetes, and on
average theywere at low risk for CVD events within ten years according
to any algorithm used (their mean risks ranged from 10.6% [s.d.= 6.1%]
calculated using the JBS/BNF equation to 14.4% [s.d. = 7.4] calculated
using the Assign equation). The prevalence of detectable HS-CTnT and
CAC were 17.9% and 55.6% (77 and 239 participants, respectively). Out
of the 191 participants without CAC, 11.0% (n = 21, 95%CI = 6.9% to
16.3%) had detectable HS-CTnT. The sample is further described in
Table 1.
Table 2 and Fig. 1 show the results of the ROC analysis. The score
based on age and gender (reference) was a better predictor for detect-
able HS-CTnT compared with any other: the area under the ROC curve
for age and gender was 0.79 (95%CI = 0.75 to 0.83), for Q-Risk2 score
was 0.76 (95%CI = 0.72 to 0.80; P value against age and gender =
0.047), for Framingham was 0.70 (95%CI = 0.66 to 0.75; P = 0.002),
for JBS/BNF was 0.69 (95%CI = 0.64 to 0.73; P = 0.001), and for Assign
score was 0.68 (95%CI = 0.64 to 0.73; P = 0.003).
Table 3 shows the results of the mediation models. The 6.8%
(95%CI =−0.1% to 13.8%) of the effect of age and gender on HS-CTnT
was mediated by CAC (referent model), whereas this proportion was
9.7% for Q-Risk 2 score (95%CI = 1.6% to 17.8%; P value against age
and gender = 0.245), 16.9% for Framingham (95%CI = 7.5% to 26.3%;
P = 0.018), 17.8% for JBS/BNF (95%CI = 7.4% to 28.2%; P = 0.019),
and 17.7% for Assign score (95%CI = 6.4% to 29.0%; P = 0.029). The
full output from the mediation models is presented in an on-line sup-
plementary data ﬁle.
Therefore, when the risk algorithms are ranked according to the
magnitude of ROCareas, the age and gendermodel comesﬁrst, followed
byQ-Risk2, Framingham, JBS/BNF, andAssign (Table 2). However,when
the scores are ranked according to the extent of mediation by CAC, their
order is essentially reversed (Table 3). Consequently, themore accurate
a score is in predicting detectable HS-CTnT the less it is mediated by
CAC. In otherwords, themore able a score is in capturing atherosclerosis
the less it is able to predict cardiac damage. The P for trend was 0.009.
The sensitivity analyses gave similar results comparedwith themain
analysis.
Discussion
Our results show that a risk model based on age and gender is more
accurate in predicting the presence of detectable concentrations of car-
diac Troponin T using a high-sensitivity assay compared with several
widely-used algorithms for the prediction of CVD events within ten
years that use additional risk factors such as lipid proﬁle and blood pres-
sure.We have also ascertained that the predictions aremediated by cor-
onary calciﬁcation to a greater extent for these algorithms compared
with age and gender alone, and we found a trend showing that the
more accurate a score is in predicting detectable HS-CTnT the less it is
mediated by CAC. This suggests that mechanisms other than extent of
coronary atherosclerosis may operate in determining ischaemia and/
or that phenomena other that ischaemia may cause CVD. Moreover,
since the risk scores typically take age and sex into account, the poorer
ability of these algorithms to identify people with detectable troponin
indicates that the inclusion of standard cardiovascular risk factors may
reduce the accuracy of predicting the processes that lead to release of
troponin T. About 11% of our participantswith absent coronary calciﬁca-
tion had detectable levels of HS-CTnT.
A strength of our study is that all participants were free from any
disease (including diabetes) and symptoms, and that no participants
were taking anti-hypertensive medications or statins, limiting issues
of confounding, interaction, and bias. On the other hand, the fact that
we have used a low risk samplemay limit the applicability of our results
to the general population (broader spectrum of risk proﬁles).
The prevalence of detectable HS-CTnT (17.9%) in our British sample
was similar to levels reported (15.7%) in a large-scale nationally-
representative CVD-free population sample in USA (De Lemos et al.,
2010). This suggests that our selection strategy was relatively unbiased,
and that the biochemical analyses in our study were comparable to
those in other investigations.
A single measure of plasma HS-CTnT concentration cannot be
regarded as a robust test if it is not stable over time, i.e. if it shows
high intra-individual short-term variation. However, the results from
the ARIC study showed that HS-CTnT intra-individual variability over
6 weeks is small, with a correlation coefﬁcient of 0.94 (Agarwal et al.,
2011).
A limitation of our study is that we did not assess the prediction
of actual future CVD events in a prospective manner, but we only con-
sidered HS-CTnT cross-sectionally. However, Troponin T is a contractile
protein that normally is not found in serum and it is released onlywhen
myocardial necrosis occurs and it is therefore highly sensitive and
speciﬁc for cardiac damage (Hillis & Fox, 1999). As a consequence, HS-
CTnT is considered to be a proximal marker of heart disease, since
the Troponin T test is at the core of the diagnosis of AMI itself
(Thygesen et al., 2007). Furthermore, our study design (cross-sectional
on disease-free and symptoms-free people) limits the possibility of
Table 1
Sample description: 430 CVD-free participants drawn from theWhitehall II epidemiolog-
ical cohort between 2006 and 2008 in United Kingdom.
Variable Mean or % SD
Age (years) 62.8 5.7
Male (%) 55.6
White ethnicity (%) 100.0
Smoker (%) 4.4
No. of cigarettes per day if smoker 15.0 8.7
Body mass index (Kg/m2) 25.7 3.8
Systolic blood pressure (mmHg) 128.5 15.3
Diastolic blood pressure (mmHg) 69.6 8.4
HDL (mmol/L) 1.7 0.5
LDL (mmol/L) 3.1 0.8
Total cholesterol (mmol/L) 5.4 0.9
Total cholesterol /HDL ratio 3.4 1.0
Glycosylated haemoglobin (mean %) 5.4 0.3
Diabetes (%) 0.0
Family history of CVD (%) 52.7
On treatment for hypertension (%) 0.0
On treatment with statins (%) 0.0
Rheumatoid arthritis (%) 0.0
Estimated risk of CVD events within 10 years (mean %)
Framingham 13.2 7.1
JBS/BNF 10.6 6.1
Assign 14.4 7.4
Qrisk2 11.4 5.5
Agatston coronary calcium score (%)
None 44.4
b100 33.7
100–399 14.2
400+ 7.7
Detectable HS-CTnT (%) 17.9
HS-CTnT concentration if detectable (geom. ng/L) 6.0 1.6
Table 2
Comparison of areas under the ROC curve for the prediction of detectable concentrations
of HS-CTnT in 430 CVD-free participants drawn from theWhitehall II epidemiological co-
hort between 2006 and 2008 in United Kingdom.
Risk score ROC Binomial exact P
Area 95% CI
Age and gender 0.79 0.75 0.83 Reference
Q-Risk 2 0.76 0.72 0.80 0.047
Framingham 0.70 0.66 0.75 0.002
JBS/BNF 0.69 0.64 0.73 0.001
Assign 0.68 0.64 0.73 0.003
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selection bias that is typical of follow-up studies. Moreover, the possibil-
ity of reverse causality (elevated levels of HS-CTnT causing increased
risk scores because of elevated levels of cholesterol, high blood pressure,
etc.) is not biologically plausible, especially for the score based on age
and gender, which are non-modiﬁable parameters.
Our results could bedistorted if our CACmeasurements did notmark
atherosclerosis accurately (information bias). However, although it has
been argued that plaque calciﬁcationmay be actually protective against
plaque rupture, the role of calciﬁcation in the progression and as a
marker of coronary atherosclerosis has been conﬁrmed, and CAC score
is considered an excellent marker of atherosclerosis (Shimizu et al.,
2012).
Non-calciﬁed coronary plaques are not detectable using cardiac
computerized tomography and therefore an explanation to our results
may be that the ‘classic’ risk factors may have an effect of plaque calciﬁ-
cation, whereas plaque formation and instability may be mainly due to
some other unknown factors. In fact, it has been argued that raised tro-
ponin Tmay be due to occult or undetected plaque rupture (Korosoglou
et al., 2011) and it is known that plaque rupture is a relatively common
event that is usually not followed by an acute cardiac event (Arbab-
Zadeh et al., 2012).
In conclusion, our results suggest that the ‘classic’ risk factors for
CVD, on which several internationally-used algorithms are based, are
not able to explain all dynamics through which cardiac cell damage is
caused. Further research is needed to identify other determinants of
CVD thatmay becomepart of risk scores andmaymake CVD risk predic-
tion more accurate.
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